The Phase IV study sponsored by Jinan Mental Hospital aims to evaluate the efficacy of Risperidone in improving the quality of life for patients with Alzheimer's Disease and Behavioral and Psychological Symptoms of Dementia (BPSD). Given the increasing prevalence of Alzheimer's disease globally, this study addresses a significant unmet need in dementia care. The collaboration with Johnson & Johnson, the manufacturer of Risperidone, suggests a strategic interest in reinforcing the drug's market position. The findings may influence prescribing practices and reimbursement policies, particularly in regions with high Alzheimer's prevalence. The study's outcomes could also provide valuable data for potential label expansions or additional indications for Risperidone, enhancing its commercial viability.